Strategies for Cancer Gene Therapy

Journal of Surgical Oncology

Volumn 85, Issue 1, 2004, Pages 28-35

  Hughes, Rhiannon M ^a,b  

^a UNIVERSITY OF CALGARY   (Canada)

^b S Alberta Cancer Research Centre   (Canada)

Author keywords

Angiogenesis; Cancer gene therapy; Drug resistance genes; Immunopotentiation; Non viral vectors; Oncogene; Suicide gene therapy; Tumor suppressor gene; Viral vectors

Indexed keywords

2 DIETHYLAMINOETHANOL; ADENOVIRUS VECTOR; ALDEHYDE DEHYDROGENASE; ANTINEOPLASTIC AGENT; ASIALOGLYCOPROTEIN; CYCLOPHOSPHAMIDE; CYTOSINE DEAMINASE; DEXTRAN; DIHYDROFOLATE REDUCTASE; ETOPOSIDE; FLUOROURACIL; GANCICLOVIR; GLYCOPROTEIN P; LENTIVIRUS VECTOR; LIPOSOME; METHOTREXATE; MULTIDRUG RESISTANCE PROTEIN 1; NAKED DNA; NANOPARTICLE; PACLITAXEL; PLASMID VECTOR; RETROVIRUS VECTOR; THYMIDINE KINASE; TRANSFERRIN; VIRUS VECTOR;

ANGIOGENESIS; BREAST CANCER; BREAST METASTASIS; CANCER CELL; CANCER CHEMOTHERAPY; CANCER CONTROL; CANCER PREVENTION; CELL DEATH; DNA PROTEIN COMPLEX; DNA REPLICATION; DNA VECTOR; DNA VIRUS; ENDOSOME; ESCHERICHIA COLI; GENE INACTIVATION; GENE REPLACEMENT THERAPY; GENETIC TRANSCRIPTION; GENETIC TRANSFECTION; GERM CELL TUMOR; HEMATOPOIETIC STEM CELL; HERPES SIMPLEX VIRUS VECTOR; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS VECTOR; IMMUNOPOTENTIATION; LYSOSOME; MOUSE MAMMARY TUMOR ONCOVIRUS VECTOR; MURINE LEUKEMIA VIRUS VECTOR; NONHUMAN; NONVIRAL GENE DELIVERY SYSTEM; NONVIRAL GENE THERAPY; ONCOGENE; PRIORITY JOURNAL; PROSTATE CANCER; REVIEW; RNA VIRUS; SPUMA VIRUS VECTOR; SUICIDE GENE; SUICIDE GENE THERAPY; TUMOR REGRESSION; TUMOR SUPPRESSOR GENE; VACCINIA VIRUS VECTOR; VIRAL GENE DELIVERY SYSTEM; VIRAL GENE THERAPY;

ADJUVANTS, IMMUNOLOGIC; DRUG RESISTANCE, NEOPLASM; GENE TARGETING; GENE THERAPY; GENES, TUMOR SUPPRESSOR; GENETIC VECTORS; HUMANS; NEOPLASMS; ONCOGENES;

EID: 0346156111     PISSN: 00224790     EISSN: None     Source Type: Journal    
DOI: 10.1002/jso.20001     Document Type: Review

References (101)

1. Ebbinghaus SW, Gee JE, Rodu B, et al.: Triplex formation inhibits HER-2/neu transcription in vitro. J Clin Invest 1993;92:2433-2439.
2. Kim HG, Miller DM: Inhibition of in vitro transcription by a triplex-forming oligonucleotide targeted to human c-myc P2 promoter. Biochemistry 1995;34:8165-8171.
3. Lavrovsky Y, Stoltz RA, Vlassov VV, et al.: C-fos protooncogene transcription can be modulated by oligonucleotide-mediated formation of triplex structures in vitro. Eur J Biochem 1996;238:582-590.
4. Kim HG, Reddoch JF, Mayfield C, et al.: Inhibition of transcription of the human c-myc protooncogene by intermolecular triples. Biochemistry 1998;37:2299-2304.
5. Kim HG, Miller DM: A novel triplex-forming oligonucleotide targeted to human cyclin D (bcl-1, proto-oncogene) promoter inhibits transcription in HeLa cells. Biochemistry 1998;37:2666-2672.
6. Tolcher AW: Preliminary phase I results of G3139 (bcl-2 antisense oligonucleotide) therapy in combination with docetaxel in hormone-refractory prostate cancer. Semin Oncol 2001;28(Suppl 15):67-70.
7. Lopes D, Mayer LD: Pharmacokinetics of Bcl-2 antisense oligonucleotide (G3139) combined with doxorubicin in SCID mice bearing human breast cancer solid tumor xenografts. Cancer Chemother Pharmacol 2000;49:57-68.
8. Snyder DS, Wu Y, McMahon R, et al.: Ribozyme-mediated inhibition of a Philadelphia chromosome-positive acute lymphoblastic leukemia cell line expressing the p190 bcr-abl oncogene. Biol Blood Marrow Transplant 1997;3:179-186.
9. Bi F, Fan D, Hui H, et al.: Reversion of the malignant phenotype of gastric cancer cell SGC7901 by c-erbB-2-specific hammer-head ribozyme. Cancer Gene Ther 2001;8:835-842.
10. Jiang WG, Grimshaw D, Lane J, et al.: A hammerhead ribozyme suppresses expression of hepatocyte growth factor/scatter factor receptor c-MET and reduces migration and invasiveness of breast cancer cells. Clin Cancer Res 2001;7:2555-2562.
11. Abounader R, Lai B, Luddy C, et al.: In vivo targeting of SF/HGF and c-met expression via UlsnRNA/ribozymes inhibits glioma growth and angiogenesis and promotes apoptosis. FASEB J 2002;16:108-110.
12. Suwanal H, Matsushita H, Kobayashi H, et al.: A novel therapeutic technology of specific RNA inhibition for acute promyelocytic leukemia: Improved design of maxizymes against PML/RARalpha mRNA. Int J Oncol 2002;20:127-130.
13. Tekur S, Ho SM: Ribozyme-mediated downregulation of human metallothionein II(a) induces apoptosis in human prostate and ovarian cancer cell lines. Mol Carcinog 2002;33:44-55.
14. Cohen PA, Mani JC, Lane DP: Characterization of a new intrabody directed against the N-terminal region of human p53. Oncogene 1998;17:2445-2456.
15. Alvarez RD, Barnes MN, Gomez-Navarro J, et al.: A cancer gene therapy approach utilizing an anti-erbB-2 single-chain antibody-encoding adenovirus (AD21): A phase I trial. Clin Cancer Res 2000;6:3081-3087.
16. Strube RW, Chen SY: Characterization of anti-cyclin E single-chain Fv antibodies and intrabodies in breast cncer cells: Enhanced intracellular stability of novel sFv-F(c) intrabodies. J Immunol Methods 2002;263:149-167.
17. Simeone DM, Cascarelli A, Logsdon CD: Adenoviral-mediated gene transfer of a constitutively active retinoblastoma gene inhibits human pancreatic tumor cell proliferation. Surgery 1997;122:428-433.
18. Fueyo J, Gomez-Manzano C, Yung WK, et al.: Suppression of human glioma growth by adenovirus-mediated Rb gene transfer. Neurology 1998;50:1307-1315.
19. Minaguchi T, Mori T, Kanamori Y, et al.: Growth suppression of human ovarian cancer cells by adenovirus-mediated transfer of the PTEN gene. Cancer Res 1999;59:6063-6067.
20. Boulay J-L, Perruchoud AP, Reuter J, et al.: p21 gene expression as an indicator for the activity of adenovirus-p53 gene therapy in non-small cell lung cancer patients. Cancer Gene Ther 2000;7:1215-1219.
21. Galderisi U, Melone MA, Jori FP, et al.: PRb2/p130 gene overexpression induces astrocyte differentiation. Mol Cell Neurosci 2001;17:415-425.
22. Seki M, Iwakawa J, Cheng H, et al.: p53 and PTEN/MMAC1/TEP1 gene therapy of human prostate PC-3 carcinoma xenograft, using transferrin-facilitated lipofection gene delivery strategy. Hum Gene Ther 2002;13:761-773.
23. Tamm I, Schumacher A, Karawajew L, et al.: Adenovirus-mediated gene transfer of P16INK4/CDKN2 into bax-negative colon cancer cells induces apoptosis and tumor regression in vivo. Cancer Gene Ther 2002;9:641-650.
24. Sun X, Kanwar JR, Leung E, et al.: Gene transfer of antisense hypoxia inducible factor-1 alpha enhances the therapeutic efficacy of cancer immunotherapy. Gene Therapy 2001;8:638-645.
25. Shi W, Teschendorf C, Muzyczka N, et al.: Adeno-associated virus-mediated gene transfer of endostatin inhibits angiogenesis and tumor growth in vivo. Cancer Gene Ther 2002;9:513-521.
26. Cichon T, Jamrozy L, Glogowska J, et al.: Electrotransfer of gene encoding endostatin into normal and neoplastic mouse tissues: Inhibition of primary tumor growth and metastatic spread. Cancer Gene Ther 2002;9:771-777.
27. Kronenwett R, Graf T, Nedbal W, et al.: Inhibition of angiogenesis in vitro by alphav integrin-directed antisense oligonucleotides. Cancer Gene Ther 2002;9:587-596.
28. Semenza GL: HIF-1 and tumor progression: Pathophysiology and therapeutics. Trends Mol Med 2002;8(Suppl 4):S62-S67.
29. Paul S, Calmels B, Acres RB: Improvement of adoptive cellular immunotherapy of human cancer suing ex-vivo gene transfer. Curr Gene Ther 2002;2:91-100.
30. Insug O, Ku G, Ertl HC, et al.: A dendritic cell vaccine induces protective immunity to intracranial growth of glioma. Anticancer Res 2002;22:613-621.
31. Simons JW, Mikhak B: Ex-vivo gene therapy using cytokine-transduced tumor vaccines: Molecular and clinical pharmacology. Sem Oncol 1998;25:661-676.
32. Zeytin HE, Tripathi PK, Bhattacharya-Chatterjee M, et al.: Construction and characterization of DNA vaccines encoding the single-chain variable fragment of the anti-idiotype antibody 1A7 mimicking the tumor-associated antigen disialoganglioside GD2. Cancer Gene Ther 2000;7:1426-1436.
33. Carsana M, Tragni G, Nicolini G, et al.: Comparative assessment of TCRBV diversity in T lymphocytes present in blood, metastatic lesions, and DTH sites of two melanoma patients vaccinated with an IL-7 gene-modified autologous tumor cell vaccine. Cancer Gene Ther 2002;9:243-253.
34. Fujii S, Huang S, Fong TC, et al.: Induction of melanoma-associated antigen systemic immunity upon intratumoral delivery of interferon-γ retroviral vector in melanoma patients. Cancer Gene Ther 2000;7:1220-1230.
35. Yazawa K, Fisher WE, Brunicardi FC: Current progress in suicide gene therapy for cancer. World J Surg 2002;26:783-789.
36. Freeman SM, Whartnby KA, Koeplin DA, et al.: The "bystander effect": Tumor regression when a fraction of the tumor mass is genetically modified. Cancer Res 1993;53:5274-5283.
37. Wygoda MR, Wilson MR, Davis MA, et al.: Protection of herpes simplex virus thymidine kinase-transduced cells from ganciclovir-mediated cytotoxicity by bystander cells: The Good Samaritan effect. Cancer Res 1997;57:1699-1703.
38. Moolten F: Tumor chemosensitivity conferred by inserted herpes thymidine kinase genes: Paradigm for a prospective cancer control strategy. Cancer Res 1986;46:5276-5281.
39. Ellion GB, Furman PA, Fyfe JA, et al.: Selectivity of action of an antiherpetic agent, 9-(2-hydroxyethoxymethyl)guanine. Proc Natl Acad Sci USA 1977;74:5716-5720.
40. Freytag SO, Khil M, Stricker H, et al.: Phase I study of replication-competent adenovirus-mediated double suicide gene therapy for the treatment of locally recurrent prostate cancer. Cancer Res 2002;62:4968-4976.
41. Schuening FG, Storb R, Stead RB, et al.: Improved retroviral transfer of genes into canine hematopoietic progenitor cells kept in long-term marrow culture. Blood 1989;74:152-155.
42. Ward M, Richardson C, Pioli P, et al.: Transfer and expression of the human multiple drug resistance gene in human CD34+ cells. Blood 1994;84:1408-1414.
43. Boesen JJB, Nooter K, Valerio D: Circumvention of chemotherapy-induced myelosuppression by transfer of the mdr1 gene. Biotherapy 1994;6:291.
44. Hesdorffer C, Ayello J, Ward M, et al.: Phase I trial of retroviral-mediated transfer of the human MDR1 gene as marrow chemoprotection in patients undergoing high-dose chemotherapy and autologous stem-cell transplantation. J Clin Oncol 1998;16:165-172.
45. Cowan KH, Moscow JA, Huang H, et al.: Paclitaxel chemotherapy after autologous stem-cell transplantation and engraftment of hematopoietic cells transduced with a retrovirus containing the multidrug resistance complementary DNA (MDR1) in metastatic breast cancer patients. Clin Cancer Res 1999;5:1619-1628.
46. Schiedimeier B, Kühlcke K, Eckert HG, et al.: Quantitative assessment of retroviral transfer of the human mulitdrug resistance I gene to human mobilized peripheral blood progenitor cells engrafted in nonobese diabetic/severe combined immunodeficient mice. Blood 2000;95:1237-1248.
47. Abonour R, Wiliams DA, Einhorn L, et al.: Efficient retrovirus-mediated transfer of the multidrug resistance I gene into autologous human long-term repopulating hematopoietic stem cells. Nat Med 2000;6:652-658.
48. Carpinteiro A, Peinert S, Ostertag W, et al.: Genetic protection of repopulating hematopoietic cells with an improved MDR1-retroviurs allows administration of intensified chemotherapy following stem cell transplantation in mice. Int J Cancer 2002;98:785-792.
49. Chaudhary PM, Roninson IB: Expression and activity of P-glycoprotein, a multidrug efflux pump, in human hematopoietic stem cells. Cell 1991;66:85.
50. Gottesman MM, Pastan I: Biochemistry of multi-drug resistance mediated by the multidrug transporter. Annu Rev Biochem 1993;62:385.
51. Boesen JJB, Nooter K, Valerio D: Circumvention of chemotherapy-induced myelosuppression by transfer of the mdr1 gene. Biotherapy 1994;6:291.
52. Takebe N, Zhao SC, Adhikari D, et al.: Generation of dual resistance to 4-hydroperoxycyclo-phosphamide and methotrexate by retroviral transfer of the human aldehyde dehydrogenase class I gene and a mutated dihydrofolate reductase gene. Mol Ther 2001;3:88-96.
53. Lin X: Construction of new retroviral producer cells from adenoviral an retroviral vectors. Gene Ther 1998;5:1251-1258.
54. Miller DG, Adam MA, Miller AD: Gene transfer by retrovirus vectors occurs only in cells that are actively replicating at the time of infection. Mol Cell Biol 1990;10:4239.
55. Roe T, Reynolds TC, Yu G, et al.: Integration of murine leukemia virus DNA depends on mitosis. EMBO J 1993;12:2099.
56. Flasshove M, Banerjee D, Leonard JP, et al.: Retroviral transduction of human CD34+ umbilical cord blood progenitor cells with a mutated dihydrofolate reductase cDNA. Hum Gene Ther 1998;9:63-71.
57. Povey J, Weeratunge N, Marden C, et al.: Enhanced retroviral transduction of 5-fluorouracil-resistant human bone marrow (stem) cells using a genetically modified packaging cell line. Blood 1998;92:4080-4089.
58. Gallay P, Swingler S, Aiken C, et al.: HIV-1 infection of nondividing cells: C-terminal tyrosine phosphorylation of the viral matrix protein is a key regulator. Cell 1995;80:379-388.
59. Miyoshi H, Takahashi M, Gage FH, et al.: Stable and efficient gene transfer into the retina using an HIV-based lentiviral vector. PNAS 1997;94:10319-10323.
60. Naldini L, Blomer U, Gallay P, et al.: In vivo gene delivery and stable transduction of nondividing cells by a lentiviral vector. Science 1996;272:263-267.
61. Russell DW, Miller AD: Foamy virus vectors. J Virol 1996;70:217-222.
62. Wickham TJ, Mathias P, Cheresh DA, et al.: Integrins avb3 and avb5 promote adenovirus internalisation but not virus attachment. Cell 1993;73:309-319.
63. Hong SS, Karayan L, Tournier J, et al.: Adenovirus type 5 fiber knob binds to MHC class ia2 domain at the surface of human epithelial cells and B lymphoblastoid cell. EMBO J 1997;16:2294-2306.
64. Bergeison JM, Cunningham JA, Droguett G, et al.: Isolation of a common receptor for coxsackie virus B viruses and adenoviruses 2 and 5. Science 1997;275:1320-1323.
65. Harris JD, Lemoine NR: Strategies for targeted gene therapy. Trends Genet 1996;12:400-404.
66. Smith AE: Viral vectors in gene therapy. Ann Rev Microbiol 1995;49:807-838.
67. Yang Y, Wilson JM: Clearance of adenovirus-infected hepatocytes by MHC class 1 restricted CD4+ CTLs in vivo. J Immunol 1995;155:2564-2569.
68. Borgland SL, Bowen GP, Wong NCW, et al.: Adenovirus vector-induced expression of the C-X-C chemokine IP-10 is mediated through capsid-dependent activation of NF-κB. J Virol 2000;74:3941-3947.
69. Bowen GP, Borgland SL, Lam M, et al.: Adenovirus vector-induced inflammation: Capsid-dependent induction of the C-C chemokine RANTES requires NF-kappa B. Hum Gene Ther 2002;13:367-379.
70. Kotin RM, Siniscalco M, Samulski RJ, et al.: Site-specific integration by adeno-associated virus. PNAS 1990;87:2211-2215.
71. Rutledge EA, Russell DW: Adeno-associated virus vector integration junctions. J Virol 1997;71:8429-8436.
72. Zaiss AK, Liu Q, Bowen GP, et al.: Differential activation of innate immune responses by adenovirus and adeno-associated virus vectors. J Virol 2002;76:4580-4590.
73. Peplinski GR, Tsung K, Norton JA: Vaccinia virus for human gene therapy. Surg Oncol Clin N Am 1998;7:575-588.
74. Hodge JW, Abrams S, Schlom J, et al.: Induction of antitumor immunity by recombinant vaccinia viruses expressing B7-1 or B7-2 costimulatory molecules. Cancer Res 1994;54:5552-5555.
75. Gomella LG, Mastrangelo JM, McCue PA, et al.: Phase 1 study of intravesical vaccinia virus as a vector for gene therapy of bladder cancer. J Urol 2001;166:1291-1295.
76. Qin H, Valentino J, Manna S, et al.: Gene therapy for head and neck cancer using vaccinia virus expression IL-2 in a murine model, with evidence of immune suppression. Mol Ther 2001;4:551-558.
77. McCart JA, Ward JM, Lee J, et al.: Systemic cancer therapy with a tumor-selective vaccinia virus mutant lacking thymidine kinase and vaccinia growth factor genes. Cancer Res 2001;61:8751-8757.
78. Kennedy PGE: Potential uses of herpes simplex virus (HSV) vectors for gene therapy of neurological disorders. Brain 1997;120:1245-1259.
79. Glorioso JC, DeLuca NA, Fink DF: Development and application of herpes simplex virus vectors for human gene therapy. Ann Rev Microbiol 1995;49:675-710.
80. Marconi P, Krisky D, Oligino T, et al.: Replication-defective herpes simplex virus vectors for gene transfer in vivo. Proc Natl Acad Sci USA 1996;93:11319-11320.
81. Nishikawa M, Huang L: Nonviral vectors in the new millennium: Delivery barriers in gene transfer. Hum Gene Ther 2001;12:861-870.
82. Wolff JA, Malone RW, Williams P, et al.: Direct gene transfer into mouse muscle in vivo. Science 1990;247:1465-1468.
83. Mincheff M, Tchakarov S, Zoubak S, et al.: Naked DNA and adenovrial immuniztions for immunotherapy of prostate cancer: A phase I/II clinical trial. Eur Urol 2000;38:208-217.
84. Felgner JH, Kumar R, Sridhar CN, et al.: Enhanced gene delivery system and mechanism studies with a novel series of cationic lipid formulations. J Biol Chem 1994;269:2550-2561.
85. Yotsuyanagi T, Hazemoto N: Cationic liposomes in gene delivery. Nippon Rinsho 1998;56:705-712.
86. Alio SF: Long term expression of the human alpha1 antitrypson gene in mice employing anionic and cationic liposome vector. Biochem Pharmacol 1997;54:9-13.
87. Lasic DD, Martin FJ, Gavizon A, et al.: Sterically stabilized liposomes: A hypothesis on the molecular origin of the extended circulation times. Biochim Biophys Acta 1991;1070:187-192.
88. Wang C, Huang L: pH sensitive immunoliposomes mediate target-cell-specific delivery and controlled expression of a foreign gene in mouse. Proc Natl Acad Sci USA 1987;84:7851-7855.
89. Stavridis JC, Deliconstantinos G, Psallidopoulos MC, et al.: Construction of transferrin-coated liposomes for in vivo transport of exogenous DNA to bone marrow erythroblasts in rabbits. Exp Cell Res 1986;164:568-572.
90. Dzau JV, Mann MJ, Morishita R, et al.: Fusigenic viral liposome for gene therapy in cardiovascular disease. Proc Natl Acad Sci USA 1996;93:11421-11425.
91. Wagner E, Cotton M, Foisner R, et al.: Transferrin-polycation-DNA complexes: The effect of polycations on the structure of the complex and DNA delivery to cells. Proc Natl Acad Sci USA 1991;88:4255-4259.
92. Wu CH, Wilson JM, Wu GY: Targeting genes: Delivery and persistent expression of a foreign gene driven by mammalian regulatory elements in vivo. J Biol Chem 1989;264:16985-16987.
93. Ferkol T, Kaetzel CS, Davis PB: Gene transfer into respiratory epithelial cells by targeting the polymeric immunoglobin receptor. J Clin Invest 1993;92:2394-2400.
94. Wagner E, Zatloukal K, Cotton M, et al.: Coupling of adenovirus to transferrin-polylysine/DNA complexes greatly enhances receptor-mediated gene delivery and expression of transfected genes. PNAS 1992;89:6099-6103.
95. Curiel DT: High-efficiency gene transfer employing adenovirus-polylysine-DNA complexes. Nat Immunol 1994;13:141-146.
96. Forsayeth JR, Garcia PD: Adenovirus-mediated transfection of cultured cells. Biotechniques 1994;17:354-358.
97. Cotton M, Wagner E, Zatloukal K, et al.: High-efficiency rceptor-mediated delivery of small and large (48 kilobase) gene constructs using the endosome-disruption activity of defective or chemically inactivated adenovirus particles. PNAS 1992;89:6094-6098.
98. Raja-Walia R, Webber J, Naftilan J, et al.: Enhancement of liposome-mediated gene transfer into vascular tissue by replication deficient adenovirus. Gene Ther 1995;2:521-530.
99. Dolivet G, Merlin JL, Barberi-Heyob M, et al.: In vivo growth inhibitory effect of iterative wild-type p53 gene transfer in human head and neck carcinoma xenografts using glucosylated polyethylenimine nonviral vector. Cancer Gene Ther 2002;9:708-714.
100. Lim YB, Kim SM, Suh H, et al.: Biodegradable, endosome disruptive, and cationic network-type polymer as a highly efficient and nontoxic gene delivery carrier. Bioconjug Chem 2002;13:952-957.
101. Panyam J, Zhou WZ, Prabha S, et al.: Rapid endo-lysosomal escape of poly (DL-lactide-co-glycolide) nanoparticles: Implications for drug and gene delivery. FASEB J 2002;16:1217-1226.